A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer

Author： Faris Jason  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.30, Iss.4, 2012-08, pp. : 1614-1620

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

By Deenen Maarten  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1557-1565

Springer Publishing Company

Access to resources Recommend Favorite

Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma

By Keam Bhumsuk   Kim Sung-Bae   Shin Seong Hoon   Cho Byoung Chul   Lee Keun-Wook   Kim Min Kyoung   Yun Hwan-Jung   Lee Se-Hoon   Yoon Dok Hyun   Bang Yung-Jue  

Cancer, Vol. 121, Iss. 15, 2015-08 ,pp. : 2612-2617

Blackwell Publishing

Access to resources Recommend Favorite

mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy

By  

Current Cancer Drug Targets, Vol. 8, Iss. 8, 2008-12 ,pp. : 647-665

Bentham Science Publishers

Access to resources Recommend Favorite

An overview of the mTOR pathway as a target in cancer therapy

By Gentzler Ryan D   Altman Jessica K   Platanias Leonidas C  

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 5, 2012-05 ,pp. : 481-489

Informa Healthcare

Access to resources Recommend Favorite

Targeting mTOR Signaling Pathway in Ovarian Cancer

By  

Current Medicinal Chemistry, Vol. 18, Iss. 19, 2011-06 ,pp. : 2960-2968

Bentham Science Publishers

Access to resources Recommend Favorite